Business
PDS Biotechnology adds drug development executives
PDS Biotechnology adds drug development executives.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 4379M NetScientific PLC 20 January 2016 \n\nNetScientific plc\n \nPDS Biotechnology appoints Chief Medical Officer and VP of Drug Development and Manufacturing to drive its clinical programmes \n \nLondon, UK - 20 January 2016 - NetScientific plc (\"NetScientific\" or the \"Group\", AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes that its portfolio company, PDS Biotechnology, has appointed Dr. Robert Shepard, M.D., F.A.C.P. as Chief Medical Officer, and Dr. Panna L. Dutta, Ph.D. as Vice President of Drug Development and Manufacturing.\nCommenting on the appointments, NetScientific's Chief Executive Officer, Francois R. Martelet said: \"PDS Biotechnology, developers of breakthrough immunotherapeutics, is one of our key therapeutic portfolio companies. We welcome the appointment of Robert and Panna to further strengthen the Company's experienced team and drive its clinical programmes in cancer and infectious diseases forward as it ramps up to begin several Phase II trials later this year.\"\n \nThe full text of PDS Biotechnology's announcement is as follows:\n \n \nImmunotherapy Company PDS Biotechnology Strengthens Senior Management Team, Adds Two Drug Development Executives\n \nNorth Brunswick, NJ - January 20, 2016 - PDS Biotechnology, a clinical-stage biotechnology company developing cancer immunotherapies, is pleased to announce the appointments of Dr. Robert Shepard, M.D., F.A.C.P. as Chief Medical Officer, and Dr. Panna L. Dutta, Ph.D. as Vice President of Drug Development and Manufacturing.\n \nIn his role as Chief Medical Officer, Dr. Shepard will oversee all clinical development programs for the Company's Versamune® platform. PDS is currently completing a Phase I clinical trial on its lead cancer immunotherapy (PDS0101), an innovative first-in-class immunotherapy under development to treat cancers and diseases caused by infection with the human papillomavirus (HPV) such as cervical cancer, head and neck cancer and cervical intraepithelial neoplasia. PDS expects to initiate multiple Phase II clinical trials over the next 18 months, including several to evaluate PDS0101 in HPV-related early- and late-stage cancers. \n \nDr. Shepard is a leading authority on clinical oncology and immunotherapy. He has led the clin...